Antibody-based immunotherapeutic attempts in experimental animal models of prion diseases. by Sakaguchi Suehiro et al.
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Background: There has been a dramatic decrease in the risk of transmission of bovine spongiform 
encephalopathy to humans. In contrast, the risk of human-to-human transmission of variant 
Creutzfeldt-Jakob disease (vCJD) via medical treatments became potentially high since 4 vCJD 
cases were reported to be possibly transmitted via blood transfusion in the United Kingdom. 
However, no treatments are yet available for curing prion diseases. Objective: Conversion of the 
normal prion protein, PrP
C
, to the amyloidogenic PrP, PrP
Sc
, plays a pivotal role in the 
pathogenesis. Recently, certain anti-PrP or anti-37/67-kDa laminin receptor (LRP/LR) antibodies 
were shown to have the potential to cure chronically infected cells, clearing PrP
Sc
 from the cells. 
This has raised the possibility of antibody based-immunotherapy for prion diseases. This article 
aims to introduce and discuss the recently published attempts of immunotherapy in prion diseases. 
Methods: Bibliographic research was carried out using the PubMed database. Patent literature 
was searched using the UK Intellectual Property Office website. Results/Conclusion: No 
satisfying consequences in animals could be detected with anti-PrP antibodies directly infused 
into the brains of animals by the intraventricular route or by anti-PrP or anti-LRP/LR single chain 
fragment antibodies directly delivered into the brain by virus vector-mediated gene transfer. This 
is probably because such delivery systems failed to deliver the antibodies to the neurons relevant 
for the treatments.  
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1. Introduction 
Prion diseases or transmissible spongiform encephalopathies are a group of devastating 
neurodegenerative disorders that include Creutzfeldt-Jakob disease (CJD), 
Gerstmann-Sträussler-Scheinker syndrome (GSS), fatal familial insomnia (FFI), and kuru in 
humans and scrapie and bovine spongiform encephalopathy (BSE) in animals [1, 2]. A sporadic 
type of CJD accounts for 85%-90% of most of prion diseases in human beings [2]. The etiology 
of sporadic CJD remains unknown [2]. Interestingly, approximately 10% of cases are inherited, 
including those of familial CJD, GSS, and FFI [2]. These inherited diseases are etiologically 
linked to specific mutations of Prnp, the gene for prion protein (PrP) [2]. Other types of the 
diseases are caused by infectious events, including iatrogenic CJD, kuru, and variant CJD (vCJD) 
[2]. Most cases of the infectious type are iatrogenic CJDs [3-6]. Kuru is a disease that emerged 
due to ritualistic cannibalism in Papua New Guinea [7]. vCJD is thought to be transmitted from 
BSE-infected cattle via contaminated food [8, 9]. No effective therapy for these diseases has been 
developed yet. 
The advent of vCJD has raised concerns of the possibility of a disease epidemic among 
the human population [10, 11]. However, only ~160 cases of vCJD have thus far been reported in 
England and a much lesser number of cases in other countries 
(http://www.cjd.ed.ac.uk/figures.htm). This low number of vCJD cases could be attributed to the 
inefficiency of oral transmission, the species barrier between cattle and humans, and the marked 
reduction in BSE cases due to the ban on using meat and bone meal ingredients in animal feed. 
However, new cases of BSE are still reported in the United Kingdom (UK) and other countries 
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(http://niah.naro.affrc.go.jp/disease/bse/count.html). Therefore, we still have to constantly survey 
the disease. Another animal prion disease, the chronic wasting disease, is spreading within mule 
deer and elk in North America [12], raising similar health concerns of the possibility of the 
disease being transmitted to humans, causing another type of vCJD. 
Four cases of vCJD considered to be transmitted via blood transfusion have been 
reported in the UK [13-16], raising the more serious concern of human-to-human secondary 
transmission of vCJD via medical treatments or procedures. vCJD is more transmissible among 
human populations than is BSE from cattle to humans. In humans, codon 129 of Prnp is 
polymorphic, coding methionine (M) or valine (V), and is a major determinant of susceptibility to 
the disease: MM is the most susceptible; MV, intermediate; and VV, protective [17-19]. All cases 
of vCJD due to BSE, reported to date, have been found in MM individuals [20]. No MV or VV 
cases have been identified thus far [20]. However, one case of blood transfusion-related vCJD 
was heterozygous at codon 129 [14]. These results suggest that vCJD might be transmissible to 
humans with any genotypes of Prnp. Consistent with these results, it was shown that vCJD was 
transmitted to mice expressing human PrP with MM, MV, or VV [20]. Thus, it is believed that 
there might be a considerable number of individuals who are latently infected with vCJD without 
any clinical symptoms, and that these latently infected people might become the sources of 
secondary transmission of vCJD. Indeed, Hilton et al. reported a much greater incidence of the 
disease than that so far reported for conventional human prion diseases. They showed that 3 out 
of 12,674 surgically removed appendectomy or tonsillectomy specimens were positive for 
staining of PrP
Sc




that in vCJD [21]. Therefore, the development of therapeutic and/or prophylactic measures for 
prion diseases is urgently awaited.  
Recently, in addition to chemical compound-based conventional therapeutic 
approaches, a new approach of antibody-based immunotherapeutics is being attempted using 
experimental animal models of prion diseases. Here, we will introduce and discuss such 
immunotherapeutic attempts. 
 
2. Therapeutic targets for prion diseases 
The causative agents of prion diseases, the so-called prions, are thought to be composed of the 




 is generated via the 
conformational conversion of the normal cellular isoform of PrP, PrP
C
, a membrane glycoprotein 
anchored to the cell surface via a glycosylphosphatidylinositol (GPI) moiety and expressed in 
various tissues, with the highest expression in the brain, particularly in neurons [22, 23]. 





plays a pivotal role in the pathogenesis of prion diseases. Indeed, along with other researchers’ 




) mice, in which the conversion never occurs 
due to lack of PrP
C
, were resistant to the diseases even after inoculation with mouse-adapted 
prions [24-27]. Moreover, it was reported that the removal of PrP
C
 specifically from the infected 
neurons rescued mice from the disease [28, 29], indicating that neurons undertaking the 
conversion may undergo degeneration. Therefore, inhibition of the conversion in the brain, 
particularly in neurons, may be therapeutic for prion diseases. 
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Yokoyama et al. carried out histoblot analysis of scrapie prion-infected mouse and 
hamster brains and showed that immunoreactive signals against PrP
C
 were decreased in the 
affected regions whereas those against PrP
Sc
 were increased [30]: this suggested that constitutive 
conversion might lead to a decrease in PrP
C
 in the brains and that the resultant functional 
impairment of PrP
C
 might be involved in the pathogenesis. Indeed, Prnp
0/0
 mice spontaneously 
developed abnormal phenotypes, some of which are often observed in prion diseases, including 
behavioral alterations in circadian activity and sleep, and demyelinated axons in the spinal cord 
and peripheral nerves [31-34]. It is therefore possible that such abnormalities in prion diseases 
might be attributable to the functional loss of PrP
C
. Thus, approaches to enhance the function of 
PrP
C
 might be alternatively therapeutic against prion diseases. However, the physiological 
function of PrP
C
 remains unknown. In contrast to the reduction in PrP
C
, constitutive conversion 
causes the accumulation of PrP
Sc
 in the brain. It is therefore suggested that PrP
Sc
 might be a toxic 
neurodegenerative molecule. Indeed, the accumulation of PrP
Sc
 is well correlated to pathological 
changes, including gliosis, spongiform changes, and neuronal cell death [2]. Moreover, an 
amyloidogenic PrP peptide, PrP106-126, or purified PrP
Sc
 was shown to be toxic to cultured cells, 
inducing apoptotic cell death [35-37]. Therefore, approaches that lead to the protection of neurons 
from PrP
Sc
 neurotoxicity might also be therapeutic. 
 
3. Anti-prion chemical compounds 
A large number of chemical compounds were screened for anti-prion activity or activity that 
reduces the total amount of PrP
Sc
 in chronically infected cultured cells, such as scrapie 
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prion-infected mouse neuroblastoma N2a cells [38, 39]. As a result, many compounds have been 
isolated as therapeutic candidates for prion diseases (Table 1). However, the chemical 
characteristics of these compounds are diverse and, for most of them, the exact mechanism of the 
anti-prion activity remains unknown.  
The compounds that could reduce PrP
Sc
 levels in infected cells were then tested for 
their therapeutic usefulness in prion-infected animals. These compounds showed prophylactic 
effects on the disease, prolonging incubation times or rescuing the animals from the disease when 
administered to animals before or immediately after prion inoculation [38, 39]. However, no 
curable effects of these compounds could be detected [38, 39]. Prolongation of incubation times 
became marginal and no animals were rescued from the disease when the compounds were 
administered at an advanced stage or in the clinical phase of the disease. This therapeutic 
ineffectiveness of the compounds is probably because the compounds fail to efficiently reach the 
therapeutically relevant brain regions due to their inability to cross the blood-brain barrier (BBB) 
or their inadequate spreading within the brain parenchyma even after direct administration into 
the brain. It is also conceivable that the compounds might be less effective against prions in the 
brain at an advanced clinical stage of the disease. Recently, De Luigi et al. reported that even a 
single intracerebroventricular infusion of liposome-entrapped doxycycline and minocycline, 
termed LipoDoxycycline and LipoMinocycline, respectively, into hamsters at an advanced stage 
of prion disease could significantly extend incubation times by 10 and 14 days, respectively [40]. 
It is thus interesting to investigate whether or not continuous or multiple infusions of the 
compounds could be more effective and cure animals of prion diseases. 
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Only a few compounds have been clinically tested against prion diseases so far. 
However, no patients have been reported to be cured from the diseases by treatment with these 
compounds, although some reports have shown that clinical symptoms, such as decreased 
cognitive activities, appeared to be slightly improved. Pentosan polysulfate (PPS) is a polyanionic 
compound exhibiting marked anti-prion activity in prion-infected cells by blocking the binding of 
the 37/67-kDa laminin receptor (LRP/LR), a possible prion receptor, to PrP
Sc
 on the cell surface 
[41], and was directly injected into the brain ventricle of patients with various types of prion 
diseases [42, 43]. Bone et al. showed that the mean survival of all treated patients was longer than 
the reported values for non-treated patients [43]. However, due to lack of proper controls, the 
therapeutic benefits of PPS remain to be proven. Quinacrine, an anti-malarial agent, has anti-prion 
activity. A large-scale randomized controlled clinical trial of quinacrine is being undertaken in the 
UK as the PRION-1 study (http://www.ctu.mrc.ac.uk/studies/cjd.asp). Nakajima et al. reported 
transient and modest improvement in mood or cognitive function by treatment of 3 patients with 
quinacrine [44]. Flupirtine is a centrally acting, non-opiate analgesic compound as also an 
anti-apoptotic agent. A double-blind, placebo-controlled study in 28 CJD patients by Otto et al. 
showed that flupirtine improved patients’ scores on several different dementia tests as compared 
to placebo [45]. These treatments were clinically unsuccessful probably because of the same 
reasons for which the compounds were ineffective in animal models. Thus, appropriate chemical 
modifications that enable the compounds to efficiently cross the BBB would be required for the 
compounds to be more effective. In addition, the compounds were administered to clinically 
advanced patients due to the lack of effective procedures that can diagnose presymptomatic 
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individuals, which might have reduced the anti-prion activity of the compounds. Therefore, the 
development of more sensitive diagnostic techniques for the detection of preclinical patients is 
essential.  
 
4. Antibodies cure chronically infected cultured cells  
4.1 Anti-PrP antibodies 
Peretz et al. first reported that recombinant PrP-specific Fab fragments cured chronically infected 
N2a cells [46]. They added PrP-specific Fab fragments, termed D13, D18, R1, R2, E123, E149, 
and R72, to chronically infected N2a cell cultures for 7 days. The anti-prion activity of the Fab 
fragments was then assessed by calculating the values of 50%-inhibitory concentration (IC50), the 
concentration necessary for halving PrP
Sc
 levels. Fabs D13 and D18 were most effective with the 
IC50 being 0.6 µg/ml (12 nM) and 0.45 µg/ml (9 nM), respectively. Fabs R1 and R2 were slightly 
less efficient, with the IC50 being 2.5 µg/ml (50 nM) and 2.0 µg/ml (40 nM), respectively. Prion 
infectivity was concomitantly reduced in these cells by over three orders of magnitude. Fabs D12, 
D18, R1, and R2 recognize residues 95-103, 132-156, 220-231, and 225-231, respectively, 
indicating that anti-prion activity might be independently mediated via broadly located multiple 
sites of PrP. In contrast, no reduction in PrP
Sc 
levels and prion infectivity were detected in the cells 
treated with Fabs E123, E149, and R72, which bind to residues 29-37, 72-86, and 151-162, 
respectively. Enari et al. reported similar results [47]: they added an anti-PrP monoclonal 
antibody (mAb), termed 6H4 which binds to residues 144-152 to their newly established infected 
N2a/Bos2 cells and showed that the antibody reduced PrP
Sc




4.2 Possible anti-prion mechanisms of anti-PrP antibodies 




 probably on the cell 
surface, particularly on lipid rafts, and/or along the endocytotic pathway to late 
endosomes/lysosomes [48]. It is therefore envisaged that anti-prion antibodies might interfere 
with the interaction. It has been reported that 3F4 and 13A5 mAbs, which recognize residues 
109-112 and 138-165, respectively, and the polyclonal antibody against residues 219-232 
disturbed the interaction and subsequently inhibited the conversion in a cell-free system [49, 50]. 
Another possibility is that anti-PrP antibodies might reduce PrP
Sc
 levels in infected cells by 
altering the subcellular localization of PrP
C
. Kim et al. showed that 31C6, 110, 44B1, and 72 
anti-PrP mAbs with anti-prion activity disturbed PrP
C
 internalization [51]. The 31C6 and 110 
mAbs react with residues 143-149 and the PHGGGWG sequence at residues 59-65 and 83-89 in 
the octapeptide repeat region, respectively, and 44B1 and 72 mAbs recognize discontinuous 
epitopes [51]. Perrier et al. showed that the anti-PrP mAbs SAF34 and SAF61, which react with 
the octapeptide repeat region and residues 144-152, respectively, accelerated the degradation of 
PrP
C
 in cells [52], suggesting another possibility that anti-PrP antibodies might inhibit PrP
Sc
 
formation by reducing PrP
C
. It is further possible that anti-PrP antibodies might interfere with the 
interaction of the so-called cofactor(s), which is postulated to play an important role in the 




, or both.  
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4.3 Anti-LRP/LR antibody 
It was shown that LRP/LR interacts with PrP
C
 directly between LRP/LR residues 161-179 and 
PrP residues 144-179, and indirectly between LRP/LR residues 101-160 or 180-285 and PrP 
residues 53-93 via a heparan sulfate chain of proteoglycan [53, 54]. Subsequently, LRP/LR was 
also demonstrated to act as the cell-surface receptor for PrP
C
 [55] and PrP27-30, the proteinase 
K-resistant core of PrP
Sc
 [41]. These indicate that LRP/LR might be involved in PrP
Sc
 formation. 
Indeed, Leucht et al. reported that the LRP/LR-specific polyclonal antibody, termed W3, 
competed with recombinant PrP for binding to the LRP/LR expressed on the cell surface, reduced 
PrP
Sc
 levels in infected N2a cells, and finally cured the cells [56]. This result indicates that W3 
might inhibit PrP
Sc
 formation by disturbing the interaction between PrP
C
 and LRP/LR. W3 was 
also shown to reduce PrP
C
 levels in cells [56]. It is thus alternatively possible that the 
W3-mediated dissociation between LRP/LR and PrP
C
 might destabilize PrP
C
, or that 
LRP/LR-PrP
C
-W3 complexes might stimulate the internalization of PrP
C
 into lysosomes for 
degradation, resulting in inhibition of PrP
Sc
 formation. Thus, LRP/LR might be a therapeutic 
target of prion diseases [57-60]. 
 
5. Immunotherapeutic attempts in experimental animal models of prion diseases 
5.1 Direct infusion of anti-PrP antibodies into the brain 
In a previous study, we produced anti-PrP mAbs, termed 3S9 and 2H9 that recognize residues 
141-161 and 151-221, respectively, and showed that both mAbs have anti-prion activity, reducing 
PrP
Sc
 levels in infected N2a cells [61]. The IC50 value of 3S9 mAb was 0.6 nM, which was over 
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10 times stronger than that (8.4 nM) of 2H9 mAb. Hence, we were interested in studying the 
immunotherapeutic potential of 3S9 mAb against prion diseases. Antibodies are macromolecules 
and are, therefore, unable to pass the BBB. White et al. demonstrated that prophylactic 
intraperitoneal administration of two anti-PrP mAbs, ICSM 18 and 35 [62], could protect mice 
from the peripheral infection of RML prions but had no effects on prions directly introduced into 
the brains of mice [63]. This could be due to the incapability of the antibodies to cross the BBB. 
Therefore, we directly administered 3S9 mAb into the right ventricle of mice that had been 
intracerebrally inoculated with a mouse-adapted Fukuoka-1 prion (SS and DI, unpublished data). 
The antibody was continuously delivered into the ventricle using the ALLZET mini-osmotic 
pump model 2004 (DURECT Corporation) at a flow rate of 0.25 ± 0.05 µg/h for 28 days from 8 
or 13 weeks post inoculation (p.i.), which corresponds to the middle or late disease stage, 
respectively. Mice infused with control IgG antibody at 8 or 13 weeks p.i. developed the disease 
at 117.8 ± 9.9 and 121.2 ± 2.5 days p.i. and eventually died at 122.5 ± 6.1 and 124.0 ± 3.7 days 
p.i., respectively (Table 2). Unexpectedly, no significant extension in incubation times and 
survival times could be detected in mice treated with 3S9 mAb. The mice treated at 8 or 13 weeks 
p.i. succumbed to the disease at 127.0 ± 9.0 (P = 0.158, Logrank test) and 125.0 ± 4.7 days p.i. (P 
= 0.851) and died at 130.0 ± 11.7 (P = 0.272) and 127.2 ± 5.8 days p.i. (P = 0.942), respectively 
(Table 2). In contrast, PrP
Sc
 levels were reduced in the brains of mice treated with 3S9 mAb at 8 
weeks p.i. to half of those in the control mice. However, no decrease in PrP
Sc
 levels could be 
observed in mice treated at 13 weeks p.i. 
On the other hand, Song et al. reported that 31C6 mAb carrying anti-prion activity (0.7 
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nM IC50) could marginally but significantly prolong survival times in mice that had been 
intracerebrally inoculated with Chandler prion [64]. The dose of the mAb used was twice (0.5 
µg/h) that of 3S9 mAb (0.25 µg/h) used by us. The mAb was infused for 28 days into the left 
ventricle of the mice at 60 (corresponding to the early stage), 90 (the middle stage), or 120 days 
p.i. (the late stage). The treated mice survived the disease by approximately 10 days more than did 
the control mice, regardless of the time points of treatment. Moreover, milder pathologies 
including PrP
Sc
 accumulation, gliosis, and vaccuolation were consistently observed in the brains 
of the treated mice. Interestingly, 31C6 mAb was less effective against a different Obihiro prion. 
Mice inoculated with an Obihiro prion could survive the disease by approximately 10 days more 
than the control mice, only when the treatment was started at 60 days p.i., but not at 90 and 120 
days p.i. These results suggest that the anti-prion effect of anti-PrP antibodies may differ for each 
of the prion strains.  
 
5.2 Virus vector-mediated gene delivery of anti-PrP scFv antibodies 
The direct intraventricular infusion of anti-prion antibodies presented only slight therapeutic 
benefits against prion disease in mice. Due to their higher molecular weight, the intraventricularly 
injected antibodies are unable to infiltrate regions where neurons mediating vital functions are 
infected by prions at concentrations that are sufficiently high for the antibodies to exert 
therapeutic effects. Indeed, Lefebvre-Roque et al. observed that, compared to whole IgGs, lower 
molecular weight F(ab’)2 fragments were more widely distributed at higher concentrations in the 
brain of mice when intraventricularly injected [65]. Therefore, a reduction in the molecular size of 
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anti-PrP antibodies without reducing their anti-prion activity might be helpful in overcoming this 
problem [66]. It has already been shown that fragmented anti-PrP antibodies, such as Fab and 
scFv antibodies, remain active against PrP
Sc
 formation in infected cells [67, 68]. However, Fab 
and scFv antibodies have the disadvantage of a short half-life, compared to full-length antibodies. 
Therefore, such fragmented anti-PrP antibodies require to be modified to overcome this problem. 
In addition, the development of systems for the efficient delivery of the fragmented antibodies 
into the brain, particularly to neurons relevant for therapy, would be very important to increase the 
therapeutic benefits of the antibodies in prion diseases.  
Recently, the anti-PrP potential of anti-PrP scFv fragments was investigated in mice 
using a virus vector-mediated brain delivery system [69]. Several serotypes of recombinant 
adeno-associated vector (rAAV) are useful as gene delivery vehicles to treat neurological 
disorders due to their efficient gene transduction into neurons and their safety profiles [70-72]. 
However, there exist several potential limitations for using the vectors. The first is the efficiency 
of gene delivery to target cells. Serotype 2 of rAAV (rAAV2) is the most commonly studied 
vector. rAAV2 preferentially transduces neurons in various regions of the brain, including the 
hippocampus, substantia nigra, and cerebellum, and in spinal cord. The transduction efficiency 
varies from one region to another. rAAV1 and rAAV5 have higher transduced distribution and 
number of neurons than does rAAV2. rAAV1 transduces neurons, and glial and ependymal cells: 
and rAAV5, neurons and astrocytes. In contrast, rAAV4 almost exclusively transduces ependymal 
cells. Prions affect neurons throughout the brain. Therefore, rAAV1 and rAAV5 may be more 
effective as therapeutic gene delivery vectors in prion diseases than would be rAAV2. However, it 
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may be difficult for even rAAV1 and rAAV5 vectors to extend to regions remote from the injected 
site. Therefore, multiple injections or further development of the vectors to transduce all of the 
target cells would be required. The second limitation is the presence of preexisting or newly 
induced anti-AAV neutralizing antibodies. No report has shown that the preexisting antibodies 
influence the transduction efficiency of rAAV. In contrast, the repeated administration of rAAV 
into the airway surface has been shown to produce an increased titer of the antibodies and 
reduced the transduction efficiency [73, 74]. However, it was reported that repeated injection of 
rAAV vectors into the rat or mouse brain was possible [75, 76]. The third limitation is the 
duration of the expression of a delivered gene. The stable expression of an rAAV2-delivered gene 
was observed at least up to 9 months in the rat brain [71].  
Wuertzer et al. generated an rAAV2 vector encoding anti-PrP scFv fragments, termed 
scFv 3:3, scFv 6:4, scFv 6:6, and scFv D18 [69]. Each rAAV2 scFv vector with 9 × 10
9
 
expression units was bilaterally injected into the thalamus and striatum of mice: and 1 month later, 
the mice were intraperitoneally inoculated with RML prions [69]. Mice treated with the control 
vector developed the disease at 199 ± 1 days p.i. No significant prolongation in incubation times 
could be detected in mice injected with rAAV scFv 6:4 and 6:6. However, mice injected with 
rAAV scFvs 3:3 and D18 showed significantly extended incubation times of 222 ± 13 and 250 ± 
8 days p.i., respectively. Reduced accumulation of PrP
Sc
 was also observed in the brains of mice 
injected with rAAV scFvs D18. These different anti-prion activities of the rAAV scFvs were well 
correlated to their binding affinity to recombinant PrP. These results indicate that anti-PrP scFv 




 formation in the brains. However, regions expressing scFvs appeared restricted to sites 
where the rAAV2 scFvs were injected. Thus, the incomplete prophylactic prevention of the 
disease by rAAV2 vector-mediated gene transfer of the anti-PrP scFv fragments might be 
attributable to this limited regional expression of the scFvs in the brain. Campana et al. produced 
another lentivirus vector for scFv D18 and tested it for its anti-prion activity in prion-infected N2a 
cells [68]. Results showed that the lentivirus could transduce scFv D18 in the cells more 
efficiently than could rAAV2 [68]. However, as in the case of the rAAV2-mediated gene transfer, 
the transduction efficiency of anti-PrP scFv fragments in the brain might be low even with 
lentivirus-mediated gene transfer.  
 
5.3 Toxic anti-PrP antibodies 
In contrast to the beneficial effects of anti-PrP antibodies, neurotoxic effects were reported with 
some anti-prion mAbs or Fab fragments. Solforosi et al. showed that anti-PrP D13 and P mAbs 
each recognizing epitopes within the residues 95-105 of PrP were toxic, causing neuronal cell 
death in normal mice when directly injected into the hippocampus or the cerebellar cortex [77]. In 
contrast, another anti-PrP D18 mAb against the residues 133-157 did not manifest any 
neurotoxicity [77]. Lefebvre-Roque et al. also reported that anti-prion 4H11 mAb or its F(ab’)2 
fragment induced extensive neuronal cell death and marked gliosis over the brain when 
administered daily for 2 weeks into the lateral ventricle of Tg20 mice that had been infected with 
the 6PB1 mouse-adapted BSE prion by the intraperitoneal route [65]. The treatment was initiated 
in the early stage of neuroinvasion (85 days p.i.) [65]. The neuronal loss was observed in regions 
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close to the injected lateral ventricle as well as in the occipital cortex, the hippocampus, the 
thalamus, and the striatum. No significant difference in the survival times could be detected 
between treated and untreated groups. Mice treated with 4H11 mAb or its F(ab’)2 fragment died 
at 140 ± 8 and 143 ± 14 days p.i. against 143 ± 10 and 144 ± 11 days p.i. for the control IgG and 
F(ab’)2 fragment, respectively. However, we detected no neuronal loss in the brains of mice 
inoculated with 3S9 mAb (SS and DI, unpublished data). No neurotoxicity was also reported in 
mice injected with 31C6 mAbs [64]. The neurotoxic 4H11, D13, and P mAbs bind to epitopes 
located within the N-terminal part of PrP. 4H11 mAb binds to the OR region (residues 51-90), 
and D13 and P mAbs recognize epitopes within residues 95-105. In contrast, nontoxic 3S9 and 
31C6 mAbs bind to epitopes within residues 141-161 of the C-terminal part of PrP. Thus, the 
binding of anti-PrP antibodies to certain regions within the N-terminal part, such as the OR region 
or residues 95-105, might elicit a neurotoxic signal by either activating or adversely preventing 
the physiological function of PrP
C
 in neurons.  
 
5.4 Anti-LRP/LR antibody 
To investigate the prophylactic anti-prion activity of the polyclonal anti-LRP/LR antibody W3 in 
vivo, W3 was peripherally injected into mice via the intraperitoneal route once a week over a 
period of 12 weeks [78]. The mice were intraperitoneally inoculated with RML prions 1 week 
after the first W3 injection. No significant prolongation in incubation times or survival was 
detected in the treated mice, probably due to the inability of the antibody to cross the BBB. 
However, PrP
Sc
 levels were reduced by 17% in the brains and by 66% in the spleens of the mice, 
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compared to those in control mice, indicating that W3 could interfere with peripheral but not the 
neuronal formation of PrP
Sc
 [78]. Similar results were reported with anti-LRP/LR scFv fragments, 
termed S18 [79, 80]. S18 scFv reduced PrP
Sc
 by approximately 40% in the spleens of mice 
infected with RML prions when intraperitoneally injected once a week for 8 weeks from 1 day 
prior to the infection. These results clearly indicate that anti-LRP/LR antibody or scFv is active in 
vivo and is able to reduce PrP
Sc
 levels.  
 Zuber et al. used rAAV2 as a vector for anti-LRP/LR scFvs to be transduced into the 
brain [81]. They generated rAAV2 encoding two different scFvs, S18 and N3, and injected 5 × 
10
9
 particles of each rAAV2 scFv into the hippocampus of mice that were inoculated with RML 
prions in the same area 2 weeks after rAAV2 scFv injection [81]. Thereafter, anti-LRP/LR scFvs 
were produced in the mouse brains. However, in contrast to the results of Wuertzer et al. [69], 
which showed that rAAV2 encoding anti-PrP scFvs 3:3 or D18 fragment was partially 
prophylactic, no prolongation in incubation times or survival was observed in mice that received 
rAAV2 scFv-S9 or N3. The authors suggested that the rAAVs might not have reached all the 
relevant brain cells that were infected by prions. Alternatively, anti-LRP/LR scFvs might be less 
effective in preventing PrP
Sc
 formation than are anti-PrP scFvs. Interestingly, the injected rAAV2s 
appeared to cross the BBB and also reach the spleen, where scFvs S18 and N3 were expressed 
and PrP
Sc
 levels were reduced by approximately 32% and 60%, respectively [81].  
 
5.5 PrP-Fc2 




 linked to the N-terminus of IgG Fc, showed marked resistant to RML prions, 
developing the disease with significantly prolonged incubation times and accumulating much less 
PrP
Sc





, but the PrP
C 
part could not be converted to PrP
Sc
 probably due to fusion 
with Fc. The authors therefore suggested that PrP-Fc2 might inhibit PrP
Sc
 formation by a 





intercalation between the two molecules, resulting in the prevention of PrP
Sc
 formation [82]. The 
same group further investigated the prophylactic activity of lentivirus vector-transduced PrP-Fc2 
against RML prions [83]. The PrP-Fc2 lentivirus was injected into the hippocampus. When the 
mice were intracerebrally inoculated with RML prions 20 days after the virus injection with 3 × 
10
8
 infectious units, the mice developed the disease with prolonged incubation times by 36 days 
as compared to the control mice, which developed the disease at 175 ± 5 days p.i. Importantly, 
this prophylactic effect of lentivirus vector-transduced PrP-Fc2 further increased when the virus 
vector was transduced into the brain with higher infectious units [83]. When mice were treated 
with 1.5 × 10
9
 infectious units of the virus vector, the incubation times were further prolonged by 
72 days (treated vs. control mice, 247 ± 8 vs. 175 ± 5 days p.i.). However, when the virus (1.5 × 
10
9
 infectious units) was injected 30 days after prion inoculation, the post-exposure prophylactic 
effect of PrP-Fc2 was reduced in the mice, but the incubation times remained significantly 
extended by 25 days. No curative effect of the lentivirus vector-transduced PrP-Fc2 was observed 
in mice when the vector was injected at 121 days p.i. (the late stage of disease) [83]. The treated 
and control mice succumbed to the disease at 197 ± 9 and 197 ± 17 days p.i., respectively. 
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5.6 Potential unfavorable responses in the immunotherapy 
Because PrP
C
 is a host-encoded glycoprotein expressed in various normal tissues, no immune 
responses are evoked against PrP
C
 under physiological conditions as well as PrP
Sc
 in prion 
diseases. LRP/LR is also a host-encoded protein. Therefore, exogenously injected antibodies 
against PrP and LRP/LR might cause autoimmune reactions in vivo although no abnormal 
symptoms have been reported in mice peripherally administered with anti-PrP or anti-LRP/LR 
W3 antibodies [63, 78]. Moreover, the injected antibodies might generate detrimental signals 
upon binding to PrP
C
 or LRP/LR. Indeed, as described above, certain anti-PrP mAbs elicited 
neurotoxic signals by cross-linking of PrP
C
 when injected into the brain [65, 77]. Thus, the 
possibility that these unfavorable effects might be induced by antibody-based immunotherapy for 
prion diseases should be carefully considered.  
 
6. Expert opinion 
No complete cure of prion diseases in animals has been obtained with anti-PrP antibodies directly 
infused into the brain by the intraventricular route or by anti-PrP and anti-LRP/LR scFvs and 
PrP-Fc2 directly delivered into the brain by virus vector-mediated gene transfer. This is probably 
because the antibodies could not infiltrate into the brain due to their higher molecular weight and 
because the virus vectors infected only those neurons that were located at or surrounding sites 
where the vectors were injected, resulting in the inability of the antibodies to reach and cure the 
infected neurons that would be essential and are relevant for effective treatments. Therefore, 
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delivery systems that are more efficient need to be developed for administering anti-PrP or 
anti-LRP/LR antibodies, scFv fragments, and PrP-Fc2 into the brain for greater therapeutic 
efficacy against prion diseases. In addition, the development of more sensitive preclinical 
diagnostic techniques is essential.  
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Table 1: Therapeutic chemical agents (see ref. 38 and 39) 
Class Chemical agents  Possible mechanisms 
Polyanionic compounds Heteropolyanion-23, Carrageenan, Dextran 
sulfate, Pentosan polysulfate, 
Glycosaminoglycans (GaGs), Heparan sulfate 
mimetics, Single-stranded phosphorothioate 
oligonucleotides, RNA aptamers, Suramin 
• Compete with endogenous 
GAGs or LRP/LR, cofactors 
important for the conversion, 













Polycationic compounds Polyamidoamide branched polymer, 
Polypropyleneimine branched polymer, 
Polyethyleneimine branched polymer, 
Cationic phosphorus-containing dendrimers, 





degradation in lysosomes 
Amyloid-binding compounds Congo red, Trypan blue, Evans blue, Sirius 






• Compete with endogenous 


















Polyene antibiotics (Amphotericin B, 
MS-8209), Statins (Lovastatin, Squalestatin, 
Simvastatin) 
• Change the properties of 
lipid raft, a possible site of 
the conversion, by binding to 
cholesterol or inhibiting 
cholesterol synthesis 
Tricyclic and related 
compounds 
Quinacrine, Tilorone, Chloroquine, Suramin, 
Chlorpromazine, Bis-acridine, Quinoline, 
2,2’-Bisquinolin, Mefloquine, Bebeerine, 
Tetrandrine, Amodiaquine, Tiotixene, 
Prochlorperazine, Thioridazine, 
• Bind to PrP
Sc
 fibrils and 





Lysosomal cystein protease 
inhibitors 
E-64, E-64d, Leupeptin • Unknown 
Cell signaling inhibitors Tyrosine kinase inhibitor (imatinib mesilate) 
Phopholipase A2 inhibitors 
(Cytidine-5-diphosphocholine, Bromoenol 
lactone, Aristolochic acid, Arachidonyl 
trifluoromethyl ketone) 
Mitogen-activated protein kinase kinase 




by inhibiting c-Able kinase 
• Inhibit PrP
Sc
 formation by 





by inhibiting MEK1/2 
activity 
Polyphenols Tannic acid, Katacine, Bisepigallocatechin 
digallate) 
• Unknown 
Anti-histamines Astemizole, Terfenadine • Unknown 






Kastellpaolitines • Unknown 
N’-Benzylidene-benzohydrazides 
 







Pridine dicarbonitrile compounds • Inhibit PrP
Sc
 formation by 







Table 2: No therapeutic effects of intraventricularly administrated-3S9 mAb in Fukuoka-1 prion-infected mice 
Treatment 
time  
Antibodies N Incubation times 









Control IgG 6 117.8 ± 9.9 122.5 ± 6.1 8 weeks p.i. 
3S9 5 127.0 ± 9.0 
0.158 
130.0 ± 11.7 
0.273 
Control IgG 5 121.2 ± 2.5 124.0 ± 3.7 13 weeks p.i. 
3S9 6 125.0 ± 4.7 
0.851 
127.2 ± 5.8 
0.942 
 
